Edition:
United States

People: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

65.82USD
21 Sep 2017
Change (% chg)

$0.03 (+0.05%)
Prev Close
$65.79
Open
$65.85
Day's High
$65.93
Day's Low
$65.67
Volume
315,060
Avg. Vol
2,829,117
52-wk High
$66.80
52-wk Low
$58.29

Schechter, Adam 

Mr. Adam H. Schechter is the Executive Vice President and President - Global Human Health of Merck & Co., Inc. He is responsible for the Company’s global pharmaceutical and vaccine business. Since November 2009 — President, Global Human Health, U.S. Market-Integration Leader, Merck & Co., Inc. — commercial responsibility in the United States for the Company’s portfolio of prescription medicines. Leader for the integration efforts for the Merck/Schering-Plough merger across all divisions and functions. Since August 2007 — President, Global Pharmaceuticals, Global Human Health, Merck & Co., Inc. — global responsibilities for the Company’s atherosclerosis/cardiovascular, diabetes/obesity, oncology, specialty/neuroscience, respiratory, bone, arthritis and analgesia franchises as well as commercial responsibility in the United States for the Company’s portfolio of prescription medicines. Since July 2006 — President, U.S. Human Health, Merck & Co., Inc. — commercial responsibility in the United States for the Company’s portfolio of prescription medicines.

Basic Compensation

Total Annual Compensation, USD 2,107,110
Restricted Stock Awards, USD 2,493,920
Long-Term Incentive Plans, USD --
All Other, USD 3,666,990
Fiscal Year Total, USD 8,268,010

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 89,200 1,807,220.00